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General  
Peptide synthesis and purification Peptides were synthesized manually by standard 
solid phase methods using HBTU/DIPEA activation of Fmoc on Rink Amide resins 
(substitution 0.30–0.50 mmol/g, 0.2–0.5 mmol scale, 0.50–1.00 g resin). 4 equiv of 
Fmoc-protected amino acid, 4 equiv of HBTU and 4 equiv of DIPEA were used in 
each coupling. Fmoc deprotection involved 2×3 min treatments with excess 1:1 
piperidine:DMF. Coupling yields were monitored by quantitative ninhydrin assay. 
Arginine residues were double coupled to prevent deletions within the sequence.  
After the final (N-terminal) residue was coupled, the compound was acetyl capped 
with 2 equiv acetic acid, 2 equiv HBTU and 2 equiv DIPEA respectively.  For cyclic 
peptides the phenylisopropyl ester of aspartic acid and methyltrityl group of lysine 
were removed by treating the peptide resin with 3% TFA in DCM (5×2 min). The 
resin was neutralised by washing with 5% DIPEA in DMF (2×3 min). Cyclization 
was effected on-resin using BOP, DIPEA in DMF. Fluorescein-labelled BAD was 
synthesised as above omitting the cyclisation and capping procedures. After the final 
glutamine was coupled the peptide was deprotected and Fmoc-6-amino hexanoic acid 
(AHA) was coupled analogously to other amino acids. Following subsequent Fmoc-
deprotection, four molar equivalents of 5(6)-carboxyfluorescein and DIC were 
coupled overnight. After synthesis the peptide resins were washed with DMF, 
MeOH/DCM and DCM, dried under nitrogen with suction for 20 min. Peptides were 
cleaved using 95% TFA, 2.5% TIPS, 2.5% H2O. Peptides were precipitated with 
diethyl ether and then decanted to give white solids that were re-dissolved in 1:1 
acetonitrile/water and lyophilised. The crude peptides were purified by rp-HPLC 
(Rt:Vydac C18 column, 300 Å 22×250 mm, 214 nm, Solvent A=0.1% TFA in H2O, 
Solvent B=0.1% TFA, 10% H2O in acetonitrile. Gradient: 0% B to 70% B over 35 
min).  
Flu-AHA-NLWAAQRYGRELRRMSDEFVDSFKK (Flu-BAD). Rt: min. MS: 
Found: [M+3H]+/3= , [M+4H]+/4= ,  [M+5H]+/5 = . Calculated: [M+H]+= . 
Ac-NLWAAQRYGRELRRMSDEFVDSFKK (BAD). Rt: 14.67 min. MS: Found: 
[M+3H]+/3= 1043.32, [M+4H]+/4= 782.44,  [M+5H]+/5 = 626.41. Calculated: 
[M+H]+= 3126.49. 
Ac-LR[K-Nle-ADD]-hPhe-NH2 (1). Rt: 15.24 min MS Found [M+H]+ = 1012.97, 
Calculated [M+H]+ = 1013.57. 
Ac-LR[KFADD]-hPhe-NH2 (2). Rt: 15.55 min MS Found [M+H]+ = 1046.86, 
Calculated [M+H]+ = 1047.55. 
Ac-LR[K-1Nal-ADD]-hPhe-NH2 (3). Rt: 15.24 min MS Found [M+H]+ = 1096.83, 
Calculated [M+H]+ = 1097.57. 
Ac-FR[K-Nle-ADD]-hPhe-NH2 (4). Rt: 15.56 min MS Found [M+H]+ = 1047.59, 
Calculated [M+H]+ = 1047.55. 
Ac-FR[KFADD]-hPhe-NH2 (5). Rt: 15.55 min MS Found [M+H]+ = 1081.49, 
Calculated [M+H]+ = 1081.53. 
Ac-FR[K-1Nal-ADD]-hPhe-NH2 (6). Rt: 16.11 min MS Found [M+H]+ = 1131.40, 
Calculated [M+H]+ = 1131.55. 
Ac-1Nal-R[K-Nle-ADD]-hPhe-NH2 (7). Rt: 16.16 min. MS Found [M+H]+ = 
1097.51, Calculated [M+H]+ = 1097.57. 
Ac-1Nal-R[KFADD]-hPhe-NH2 (8). Rt: 16.11 min. MS Found [M+H]+ = 1131.45, 
Calculated [M+H]+ = 1131.55. 
Ac-1Nal-R[K-1Nal-ADD]-hPhe-NH2 (9). Rt: 16.74 min MS Found [M+H]+ = 
1181.38, Calculated [M+H]+ = 1181.56. 
Ac-LR[K-Nle-ADD]F-NH2 (10). Rt: 15.33 min MS Found [M+H]+ = 999.04, 
Calculated [M+H]+ = 999.55. 
Ac-LR[KFADD]F-NH2 (11). Rt: 15.18 min MS Found [M+H]+ = 1032.91, Calculated 
[M+H]+ = 1033.53. 
Ac-LR[K-1Nal-ADD]F-NH2 (12). Rt: 15.89 min MS Found [M+H]+ = 1082.84, 
Calculated [M+H]+ = 1083.55. 
Ac-FR[K-Nle-ADD]F-NH2 (13). Rt: 15.23 min MS Found [M+H]+ = 1033.65, 
[M+2H]+/2 = 517.78 Calculated [M+H]+ = 1033.53. 
Ac-FR[KFADD]F-NH2 (14). Rt: 15.24 min MS Found [M+H]+ = 1067.61, Calculated 
[M+H]+ = 1067.52. 
Ac-FR[K-1Nal-ADD]F-NH2 (15). Rt: 15.77 min MS Found [M+H]+ = 1117.41, 
Calculated [M+H]+ = 1117.53. 
Ac-1Nal-R[K-Nle-ADD]F-NH2 (16). Rt: 15.74 min. MS Found = [M+H]+ = 1083.53, 
Calculated [M+H]+ = 1083.55. 
Ac-1Nal-R[KFADD]F-NH2 (17). Rt: 15.65 min MS Found [M+H]+ = 1117.51, 
Calculated [M+H]+ = 1117.53. 
Ac-1Nal-R[K-1Nal-ADD]F-NH2 (18). Rt: 16.19 min MS Found [M+H]+ = 1167.33 
Calculated [M+H]+ =1167.55. 
Ac-LR[K-Nle-ADD]-Nle -NH2 (19). Rt: 15.21 min MS Found [M+H]+ = 965.81, 
Calculated [M+H]+ = 965.57. 
Ac-LR[KFADD]-Nle -NH2 (20). Rt: 15.01 min MS Found [M+H]+ = 999.72, 
Calculated [M+H]+ = 999.55. 
Ac-LR[K-1Nal-ADD]-Nle -NH2 (21). Rt: 15.80 min MS Found [M+H]+ = 1049.65, 
Calculated [M+H]+ = 1049.57. 
Ac-FR[K-Nle-ADD]-Nle -NH2 (22). Rt: 15.17 min MS Found [M+H]+ = 999.66, 
Calculated [M+H]+ = 999.55. 
Ac-FR[KFADD]-Nle -NH2 (23). Rt: 14.98 min MS Found [M+H]+ = 1033.61, 
[M+2H]+/2 = 517.77, Calculated [M+H]+ = 1033.53. 
Ac-FR[K-1Nal-ADD]-Nle -NH2 (24). Rt: 15.56 min MS Found [M+H]+ = 1083.51, 
Calculated [M+H]+ = 1083.55. 
Ac-1Nal-R[K-Nle-ADD]-Nle -NH2 (25). Rt: 16.67 min MS Found [M+H]+ = 
1049.38, Calculated [M+H]+ = 1049.57. 
Ac-1Nal-R[KFADD]-Nle -NH2 (26). Rt: 15.61 min MS Found [M+H]+ = 1083.66, [ 
[M+H]+ = 1083.55. 
Ac-1Nal-R[K-1Nal-ADD]-Nle-NH2 (27). Rt: 16.24 min MS Found [M+H]+ = 
1133.22, Calculated [M+H]+ = 1133.57. 
Ac-1Nap-RR-Nle-ADEF-NH2 (28). Rt: min. MS Found [M+H]+ = 1143.89 
[M+2H]+/2 = 572.68, Calculated [M+H]+ = 1143.58 
Ac-1Nap-Aib-[K-Nle-ADD]F-NH2 (29). Rt: 16.31 min. MS Found [M+H]+ = 955.66 
Calculated [M+H]+ = 955.48. 
1Napprop-Aib-[K-Nle-ADD]F-NH2 (30). Rt: 16.72 min. MS Found [M+H]+ = 955.66 
Calculated [M+H]+ = 955.48. 
1Napcinn-Aib-[K-Nle-ADD]F-NH2 (31). Rt: 16.95 min. MS Found [M+H]+ = 953.85, 
[M+H]+ = 953.46. 
1NapOAc-Aib-[K-Nle-ADD]F-NH2 (32). Rt: 16.61 min. MS Found [M+H]+ = 
1028.88, Calculated [M+H]+ = 1028.51 
Ac-1Nal-Aib-[K-Nle-ADD]-3,4ClPhe-NH2 (33). Rt: 16.44 min. MS Found [M+H]+ = 
1081.15, Calculated [M+H]+ = 1080.42. 
Ac-1Nal-Aib-[K-Nle-ADD]-Ser(OBn) -NH2 (34). Rt: 16.02 min. MS Found [M+H]+ 
= 1042.88, [Calculated [M+H]+ = 1042.51. 
Ac-1Nal-Aib-[K-Nle-ADD]-2Nal-NH2 (35). Rt: 16.35 min. MS Found [M+H]+ = 
1063.34, Calculated [M+H]+ = 1062.52. 
 
Circular Dichroism CD experiments were performed on a Jasco Model J-710 
spectropolarimeter which was routinely calibrated with (1S)-(+)-10-camphorsulfonic 
acid. Spectra were recorded in a 0.1 cm Jasco cell between 260 and 185 nm at 50 
nm/min with a bandwidth of 1.0 nm, response time of 2 s, resolution step width of 0.1 
nm, and sensitivity of 20, 50, or 100 mdeg. Each spectrum represents the average of 
five scans with smoothing to reduce noise. Peptide samples for CD spectroscopy were 
dissolved in 18 MΩ distilled water (∼3−4 mg/mL). Each stock solution (500 µL) was 
then diluted 1:1 with phosphate buffer pH 7.4. Solutions were then prepared for each 
sample with final concentrations ranging from 50 to 800 µM in 10 mM sodium 
phosphate buffer (pH 7.4). Over this concentration range the CD intensity was found 
to be independent of concentration ruling out aggregation as a stabilizing effect. The 
remaining 500 µL from the initial stock solution was used for accurate concentration 
determination. Accurate concentrations of stock solutions were determined by 1D 1H 
NMR spectroscopy based on integrations of non-exchangeable proton signals using 
the method of Larive et al.53 Briefly 475 µL of the initial peptide stock solution was 
mixed with 50 µL of D2O and spiked with an internal standard, 25 µL of 10.077 mM 
DSS (. 1D 1H NMR spectra were then recorded with presaturation and a relaxation 
delay (d1) of 30 s to allow for full relaxation of peptide and DSS 1H signals to 
facilitate accurate integration of proton signals with S/N > 250:1.  
Binding affinity measured by fluorescence polarisation Fluorescence polarisation 
was used to assess the binding affinity of compounds to either Bcl-2 or Bcl-xL. 
Assays were conducted as previously described66. Briefly, the assay buffer contained 
20 mM phosphate buffer, 50 mM NaCl, 1 mM EDTA and 0.05% pluronic F-127 
(Invitrogen, CA, USA) and fluorescein-labelled BAD (Flu-BAD) was used as the 
probe.   
The equilibrium binding experiments of the fluorescein-labelled Bad peptide 
to Bcl-xL (R&D Systems) was determined in a 96-well assay plate contained 15 nM 
fluorescent peptide, and increasing concentrations of protein in assay buffer in a final 
volume of 200 µL. The plate was incubated for 20 min and then measured using 
Envision platereader (Perkin Elmer) at room temperature with an excitation 
wavelength of 480 nm and an emission wavelength of 535 nm.  Millipolarisation units 
(mP) were calculated using equation 5.1 by the Envision software.   
 
mP = ( {S – (G x P)} / {S – (G x P)} ) x 1000  
 
where S and P are background subtracted fluorescence rates and G is an instrument 
and assay dependent factor (determined for each plate). 
 
Kd values were calculated by fitting data to a sigmoidal dose-response 
nonlinear regression model using GraphPad Prism (GraphPad Software Inc., San 
Diego, CA) . 
 
The competition studies were performed in a 96-well plate contained 15 nM 
fluorescein-labelled Bad, 10 nM Bcl-xL and increasing concentrations of test 
compounds in assay buffer, in a final volume of 200 µL.  The plate was incubated at 
room temperature for 20 min and then measured as described above. The IC50, or the 
concentration at which 50% of bound peptide is displaced, was obtained by fitting the 
data to a sigmoidal dose-response nonlinear regression model (Eq. 5.2) (Prism5, 
GraphPad Software). 
 
Y = bottom + (top – bottom) / (1+10 logEC50 – X) x hillslope) 
 
 
where EC50 can also be IC50, depending on the type of experiment. 
 
Cell culture - The human leukaemia T cell line (Jurkat E6.1 cells) were cultured in 
Gibco® RPMI (Invitrogen, CA, USA) medium supplemented with 10% FBS 
(Invitrogen, CA, USA), GIBCO® Pen/Strep (50 units/mL penicillin and 50 µg/ml 
streptomycin, Invitrogen, CA, USA), GIBCO® NEAA (non-essential amino acids; 1 
x, Invitrogen, CA, USA) and GIBCO® L-glutamic acid (final concentration 2 mM, 
Invitrogen, CA, USA).  Cells were grown to 80-90% confluency at 37 °C (5% CO2) 
and were passaged at a ratio of 1:10 every three to four days.  
Cytotoxicity To assess the cytotoxicity of peptides on Jurkat E6.1 cells, we used the 
standard MTT assay. In this assay, the yellow tetrazolium salt MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) can be reduced to a purple 
formazan product in the mitochondria of metabolically active cells.  We were able to 
quantify the formation of blue formazan at 570 nm, relating absorbance to the number 
of viable cells.  We expected that the peptides would have different stability in serum 
so to minimise this effect, the MTT assays were conducted in serum-free media.   	
Jurkat T cells were washed three times in serum-free media and subsequently 
plated into a clear, flat-bottom, 96-well microtitre plate at 5x104 cells/well. Cells were 
then treated with 10 µL of peptide at various concentrations. The microtitre plate was 
then incubated for 48 hours at 37 °C (5% CO2).  MTT (Sigma-Aldrich, NY, USA) 
was added to each well (10 µL, final concentration 50 µg/mL). The treated plate was 
incubated in the dark for two hours at 37 °C (5% CO2). 10% SDS in 
water/isopropanol (1:1) was added (100 µL per well) and incubated at 37 °C 
overnight, to allow complete solubilisation of the purple formazan product. 
Absorbance was read at 570 nm, with background subtraction 630 - 690 nm, on 
BioTekPowerWave XS micro-well plate reader. A dose-response curve was obtained 
by fitting data to a sigmoidal dose-response nonlinear regression model (Eq 5.2) 
(Prism5, GraphPad Software). 
